joflupaan (123i) rotop 74 mbq/ml inj. sol. i.v. vial
rotop radiopharmacy gmbh - ioflupane (i-123) 74 mbq/ml - solution for injection - 74 mbq/ml - ioflupane (i-123) 74 mbq/ml - iodine ioflupane (123i)
ioflupan (123i) rotop 74 mbq/ml injektionslösung
datscan solution
ge healthcare canada inc - ioflupane (123i) - solution - 74mbq - ioflupane (123i) 74mbq - roentgenography
datscan solution for injection 74 mbqml
ge healthcare pte. ltd. - ioflupane (123i) - injection, solution - ioflupane (123i) 74 mbq/ml at reference time
mibgen
ansto t/a ansto health - iobenguane(123i) sulfate; iobenguane [123i] sulfate; iobenguane sulfate [123i] -
exelon patch 10
novartis new zealand ltd - rivastigmine 18mg; ; - transdermal patch - 9.5 mg/24h - active: rivastigmine 18mg excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 10 cm square release liner 20.25 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.
exelon patch 15
novartis new zealand ltd - rivastigmine 27mg; ; - transdermal patch - 13.3 mg/24h - active: rivastigmine 27mg excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 15 cm square release liner 30.375 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.
exelon patch 5
novartis new zealand ltd - rivastigmine 9mg; ; - transdermal patch - 4.6 mg/24h - active: rivastigmine 9mg excipient: dimeticone dl-alpha tocopherol acrylic pressure sensitive adhesive silicone pressure sensitive adhesive backing film 5 cm square release liner 10.125 cm square poly(butyl methacrylate-co-methyl methacrylate) - treatment of patients with: · mild to moderately severe dementia of the alzheimer's type (also termed probable alzheimer's disease or alzheimer's disease) · severe dementia of the alzheimer's type.
simulect
novartis new zealand ltd - basiliximab 10mg (murine/human; formulated with a 7.5% total overage); - powder for injection - 10 mg - active: basiliximab 10mg (murine/human; formulated with a 7.5% total overage) excipient: dibasic sodium phosphate glycine mannitol monobasic potassium phosphate sodium chloride sucrose water for injection - simulect is indicated for the prophylaxis of acute organ rejection in de novo renal transplantation in adult and paediatric patients. it is to be used concomitantly with cyclosporin for microemulsion- and corticosteroid-based immunosuppression or in a triple maintenance immunosuppressive regimen containing cyclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
simulect
novartis new zealand ltd - basiliximab 20mg (murine/human; formulated with a 7.5% total overage) - powder for injection - 20 mg - active: basiliximab 20mg (murine/human; formulated with a 7.5% total overage) excipient: dibasic sodium phosphate glycine mannitol monobasic potassium phosphate sodium chloride sucrose water for injection - simulect is indicated for the prophylaxis of acute organ rejection in de novo renal transplantation in adult and paediatric patients. it is to be used concomitantly with cyclosporin for microemulsion- and corticosteroid-based immunosuppression or in a triple maintenance immunosuppressive regimen containing cyclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.